Roka Bioscience (ROKA) Shares are Down -23.81%

Roka Bioscience (ROKA) : During the past 4 weeks, traders have been relatively bearish on Roka Bioscience (ROKA), hence the stock is down -0.42% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -24.21% relative to the S&P 500. The 4-week change in the price of the stock is -2.44% and the stock has fallen -23.81% in the past 1 week.

The stock has recorded a 20-day Moving Average of 19.41% and the 50-Day Moving Average is 8.11%.The 200 Day SMA reached 2.07% Roka Bioscience, Inc. is up 14.61% in the last 3-month period. Year-to-Date the stock performance stands at -34.96%.


The shares have received a consensus rating of Sell for the current week Roka Bioscience (NASDAQ:ROKA): stock was range-bound between the intraday low of $0.73 and the intraday high of $1 after having opened at $1 on Fridays session. The stock finally closed in the red at $1, a loss of -31.62%. The stock remained in the red for the whole trading day. The total traded volume was 930,775 shares. The stock failed to cross $1 in Fridays trading. The stocks closing price on Thursday was $0.8.

Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company has launched Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using: culture-based assays, immunochemical-based assays and molecular-based assays. The Companys Atlas instrument is a fully automated molecular diagnostic testing instrument designed to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The Atlas instrument is a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.